LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dam...

Descripción completa

Detalles Bibliográficos
Autores: Cobo-Vuilleumier, Nadia, Lorenzo, Petra I., García Rodríguez, Noelia, Herrera Gómez, Irene de Gracia, Fuente-Martin, Esther, López-Noriega, Livia, Mellado-Gil, José Manuel, Romero-Zerbo, Silvana-Yanina, Baquié, Mathurin, Lachaud, Christian Claude, Stifter, Katja, German, Perdomo, Marco, Bugliani, De Tata, Vincenzo, Bosco, Domenico, Parnaud, Geraldine, Pozo, David, Hmadcha, Abdelkrim, Florido, Javier P., Toscano, Miguel G., de Haan, Peter, Schoonjans, Kristina, Sánchez Palazón, Luis, Marchetti, Piero, Schirmbeck, Reinhold, Martín-Montalvo, Alejandro, Meda, Paolo, Soria, Bernat, Bermúdez-Silva, Francisco-Javier, St-Onge, Luc, Gauthier, Benoit R.
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/17588
Acceso en línea:http://hdl.handle.net/20.500.12105/17588
Access Level:acceso abierto
Palabra clave:Islets of Langerhans
Type 1 diabetes
Type 2 diabetes
Islotes Pancreáticos
Diabetes Mellitus Tipo 1
Diabetes Mellitus Tipo 2
Diabetes Mellitus
Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Murinae
Animals
Descripción
Sumario:Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus.

Similares en LA Referencia